Hénichart J P, Bernier J L, Catteau J P
Hoppe Seylers Z Physiol Chem. 1982 Aug;363(8):835-41. doi: 10.1515/bchm2.1982.363.2.835.
N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide, an antitumor drug which has been tested in clinical trials, is known to bind to DNA by the intercalation of its 9-aminoacridine moiety between DNA base pairs and its anilino side chain would then be located in the narrow groove. The intercalatice binding of the drug has been studied here, using ESR through competition with a spin-labelled 9-aminoacridine. In addition the affinity parameters of the parent compound 4-(9-acridinylamino)aniline and a new peptidic derivative, 4-(9-acridinylamino)-N-(lysylglycyl)aniline, have been evaluated by the same technique. Thus the influence of the side chains structures on the dissociation constant values was determined. The results reported here suggest that the affinity of this drug to DNA could be increased by the introduction of a lysyl residue.
N-[4-(9-吖啶基氨基)-3-甲氧基苯基]甲磺酰胺是一种已在临床试验中进行测试的抗肿瘤药物,已知它通过其9-氨基吖啶部分插入DNA碱基对之间与DNA结合,其苯胺侧链则位于窄沟中。本文利用电子自旋共振(ESR)通过与自旋标记的9-氨基吖啶竞争来研究该药物的嵌入结合。此外,还通过相同技术评估了母体化合物4-(9-吖啶基氨基)苯胺和一种新的肽衍生物4-(9-吖啶基氨基)-N-(赖氨酰甘氨酰)苯胺的亲和参数。由此确定了侧链结构对解离常数的影响。本文报道的结果表明,引入赖氨酰残基可提高该药物对DNA的亲和力。